



HOPA 2024
20 Years
of Optimizing Cancer Care



April 3-6, 2024 | Tampa Convention Center in Tampa, Florida



VENCLEXTA[®]
venetoclax tablets 10mg, 50mg, 100mg

**For more information on VENCLEXTA,
visit AbbVie at Booth #201**

abbvie

Genentech
A Member of the Roche Group



VENCLEXTA[®]
venetoclax tablets 10mg, 50mg, 100mg

Distributed and marketed by AbbVie Inc., 1 North Waukegan Road, North Chicago, IL 60064
Marketed by Genentech USA, Inc., 1 DNA Way, South San Francisco, CA 94080-4990
©2019 AbbVie Inc. and Genentech USA, Inc.

US-VENC-190044/April 2019 Printed in USA

2024 CONFERENCE SPONSORS

TITANIUM SPONSORS

abbvie

PLATINUM SPONSORS

AstraZeneca 

GOLD SPONSORS

 amneal

 BeiGene

GSK

pharmacy
TIMES.

REGENERON
SCIENCE TO MEDICINE™

sanofi

SILVER SPONSORS

 Bristol Myers Squibb™

Lilly

Thank you for your support!

Visit the AstraZeneca Booth at **HOPA 2024!**



IMFINZI[®]
durvalumab
Injection for Intravenous Use 50 mg/mL

IMJUDO[®]
tremelimumab-actl
Injection for Intravenous Use 20 mg/mL



CALQUENCE[®]
acalabrutinib 100 mg tablets



TAGRISSO[®]
osimertinib



Lynparza[®]
olaparib
tablets 150 mg



Truqap[®]
cavitasertib



Please scan for complete Prescribing Information, including Boxed WARNINGS and Medication Guide, or visit www.ENHERTUHCP.com

ENHERTU[®]
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

Please see Important Safety Information and full Prescribing Information, including Boxed WARNINGS, and Medication Guide, available at our booth & at www.ENHERTUHCP.com

 Daiichi-Sankyo |  AstraZeneca

ENHERTU[®] is a registered trademark of Daiichi Sankyo Company, Limited.
© 2024 Daiichi Sankyo, Inc. and AstraZeneca. PP-US-ENB-3120 2/24

For more information, please visit us at www.astrazeneca-us.com

CALQUENCE, IMFINZI, IMJUDO, LYNPARZA, TAGRISSO, TRUQAP are registered trademarks of the AstraZeneca group of companies.

©2024 AstraZeneca. All rights reserved. US-85675 Last updated 2/24

AstraZeneca 

CONTENTS

2024 Conference Sponsors	3
Welcome to HOPA2024	7
Schedule of Events	8
Wednesday, April 3	8
Thursday, April 4	10
Friday, April 5	13
Saturday, April 6	15
2024 Board of Directors Update	16
Class of 2024 HOPA Fellows	17
2024 Member Awards Winners	18
Continuing Pharmacy Education	22
General Information	26
Tampa Convention Center Map	28
Schedule for Exhibits and Posters	31
Exhibitors	33
CE Symposia	38
Non-CE Symposia	41
Industry Relations Council (IRC) Partners	47

Advertisers

AbbVie	Inside Front Cover
AstraZeneca	4
Regeneron Pharmaceuticals	6
PTCE/Pharmacy Times	20
Lilly	21
Aveo Oncology	27
BeiGene	30
Deciphera Pharmaceuticals	31
Amneal Pharmaceuticals	32
Bristol Myers Squibb	40
Servier Pharmaceuticals	45
Sanofi	46

**LIBTAYO**[®]
(cemiplimab-rwlc)
Injection 350 mg



Patient portrayal

**Explore the clinical profile of LIBTAYO
across multiple indications**

**Visit Regeneron Booth 308 at
HOPA Annual Conference 2024
or [Libtayohcp.com](https://libtayohcp.com)**

Apr 3 - Apr 6
Tampa Convention Center
Tampa, FL

Please scan QR code
to learn more



REGENERON[®]

© 2023 Regeneron Pharmaceuticals, Inc. All rights reserved.
US.LIB.23.09.0002 09/23

WELCOME TO HOPA2024



Welcome to our 20th Annual Conference and Anniversary Celebration!

We are so happy that so many of our members and colleagues in hematology/oncology pharmacy are here to learn, network and celebrate with us!

This year marks *20 Years of Optimizing Cancer Care*. When you look at all the great science and continuing education hours we have to offer, we hope you will see we have no intention of slowing down. This year, there are 35 Continuing Education (CE) credits to choose from, including 8 BCOP CEs.

I hope to see you during our many networking events, our Incoming President's Address, and our Annual Business Meeting. We hope you will celebrate this year's Member Award Winners and newly named Fellows of HOPA (FHOPA).

This year's John G. Kuhn Keynote Address will be delivered by Will "Dr. G" Flanary, MD, an ophthalmologist and two-time cancer survivor, who also just happens to have survived cardiac arrest. You may know him by his social-media persona, "Dr. Glaucomflecken," who creates medical-themed comedy shorts for an audience of over 4 million across social media. During this keynote address, Dr. Flanary will take you on a hilarious and heartfelt tour of his life in the world of medicine, both as a physician and patient. Through his experience, you will hear about the impact our healthcare system has on patients and their loved ones and what we can do to make it better.

In March 2020, we pivoted our conference in Tampa to online learning due to the challenges posed by COVID-19. Today, we take pride in continuing to offer dynamic content and exceptional speakers in a fully live environment. The conference committee and staff, in collaboration with our Diversity, Equity, and Inclusion Advisory Group, has taken the time to familiarize ourselves with Tampa. This is a city that genuinely embraces diversity and strives to be equitable and accessible for all. This aligns with our association's vision for providing the best care possible to all individuals undergoing cancer treatment. On behalf of the Annual Conference 2024 Committee, we sincerely appreciate your commitment to joining us.

Please join me in thanking the AC Committee and all the HOPA members who volunteered their time and expertise to make our conference a success. A special note of appreciation goes out to our esteemed speakers and research presenters who provide all the great science you have come to expect from HOPA.

Let's celebrate together!

A handwritten signature in black ink, appearing to read "Maribel Pereiras".

Maribel Pereiras, Pharm.D., BCPS, BCOP

Chair, Annual Conference Committee

SCHEDULE OF EVENTS

All times are Eastern Time.

All session room locations are subject to change, and attendees will be notified of schedule changes via the HOPA mobile app.

Wednesday, April 3	
7:00-8:00 AM Room 120-121	CE Symposium 1.0 CE Navigating Chronic Lymphocytic Leukemia Therapy and Cardiovascular Comorbidities: Clinical Recommendations and Safety Measures <i>This activity is supported by educational grants from BeiGene USA, Inc. and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.</i>
7:00-8:00 AM Room 122-123	CE Symposium 1.0 CE Balancing Innovation and Implementation: A Comprehensive Approach to CAR T, Bispecific Antibodies, and Operational Efficiency in Multiple Myeloma Victoria Nachar, PharmD, BCOP; Joseph A. Kalis, PharmD, BCOP; Rebecca Gonzalez, PharmD, BCOP <i>This activity is supported by an educational grant from Bristol Myers Squibb.</i>
7:00-8:00 AM Room 124-125	CE Symposium 1.0 CE Prescriptions for Successful Myeloma Care: Pharmacy Strategies for Delivering Effective Therapy with Antibody Platforms R. Donald Harvey, III, PharmD, BCOP, FCCP, FHOPA; Zahra Mahmoudjafari, PharmD, MBA, BCOP; James A. Davis, PharmD, BCOP <i>This activity is supported by independent medical education grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Regeneron Pharmaceuticals, Inc., and Sanofi.</i>
8:00 AM-12:00 PM Room 114 - 117	Pre-Conference Workshop: From Data to Decisions: A Masterclass in Critical Appraisal of Cancer Research (001) 4.0 CE K Aaron Goodman, MD; Bernard Marini, PharmD, BCOP; Anthony Perissinotti, PharmD, BCOP <i>There is a separate/extra fee for this event.</i>
12:00-1:00 PM Ballroom Pre-function Area	HOPA Board Meet and Greet: What's the Buzz? Meet with HOPA's Board of Directors over coffee (and other beverages) + sweet treats!
12:00-1:00 PM Room 120-121	Non-CE Symposium Outcomes and Economic Impact of Treatment with CABLIVI®(caplacizumab-yhdp) Hillary Maitland, MD, MS and Adam Gurry, MD, MS <i>This activity is sponsored by Sanofi.</i>
12:00-1:00 PM Room 122-123	Non-CE Symposium How Is the Treatment of Patients With KRAS G12C-Mutated Advanced NSCLC Evolving? Sandra Cuellar, PharmD, BCOP, FHOPA, FASHP <i>This activity is sponsored by Mirati -- A Bristol Myers Squibb company.</i>
12:00-1:00 PM Room 124-125	Non-CE Symposium Brukinsa (zanubrutinib) for the treatment of adult patient with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Bhavesh Shah, RPh BCOP <i>This activity is sponsored by BeiGene.</i>
1:15-2:30 PM Ballroom B-C	BCOP Session 1: Diving into DEI: Increasing Inclusivity and Fostering Diversity in Clinical Trials (BC1) 1.25 CE A Lisa Janssen Carlson, PharmD, BCOP; Elyse MacDonald, PharmD, MS, BCPS; Jennifer Murphy, PharmD, BCOP
1:15-2:30 PM Ballroom D	Updates in Hematology (101) 1.25 CE K Dennis Marjoncu, PharmD, BCOP
2:30-2:45 PM Ballroom Pre-function Area	Break
2:45-3:30 PM Ballroom B-C	President's Welcome and Recognition of 2024 HOPA Fellows LeAnne Kennedy, PharmD, BCOP, CPP, FHOPA
3:30-3:45 PM Ballroom Pre-function Area	Break

Posters and Exhibits

General Session

Commercially Supported Programming

Leadership/Practice Management

BCOP Presentation

Research

SCHEDULE OF EVENTS

All times are Eastern Time.

All session room locations are subject to change, and attendees will be notified of schedule changes via the HOPA mobile app.

Wednesday, April 3	
3:45-4:45 PM Ballroom D	Platform Research Presentations (102) 1.0 CE K
	Part 1: The REMEDY Trial: Remote Outpatient Temperature Monitoring for Early Detection of Febrile Neutropenia After High-Dose Cytarabine Consolidation Chemotherapy <i>Amber Bradley Clemmons, PharmD, BCOP, FHOPA; E. Behren Ketchum, PharmD, BCOP</i>
	Part 2: Post-Transplant Cyclophosphamide As GVHD Prevention After Myeloablative Conditioning <i>Mary C. Cash, PharmD, BCOP; Erin M. Eberwein, PharmD, BCOP</i>
	Part 3: Survey of PGY-2 Oncology RPDs To Assess Resources and Effects on Burnout <i>Eugene Przespolewski, PharmD, BCOP, DPLA</i>
	Part 4: Predictive Factors of Dose Reduction Among Patients Treated With Palbociclib <i>Sandra Savignac, PharmD, M.Sc</i>
3:45-4:45 PM Ballroom A	(103) Updates in Hodgkin Lymphoma and the Role of the Pharmacist in Management of Toxicities 1.0 CE A <i>Tiba Al Sagheer PharmD, BCOP, BCACP; Matthew Chui, PharmD, BCOP</i>
3:45-4:45 PM Ballroom B-C	(104) Waiting For The Rain: Practical Strategies And Ethical Considerations During Anticancer Drug Droughts 1.0 CE K <i>Michael Harrison, Patient Advocate and Cancer Survivor; Jeffrey Pilz, PharmD, MPA, BCPS; Peter Stuessy, PharmD, BCOP</i>
4:45-7:00 PM West Hall	Welcome Reception, Exhibits and Industry Encore Posters
5:30-6:30 PM Room 120-121	Non-CE Symposium Planning for Treatment in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Case-Based Symposium on Care Team Preparation and Patient Management <i>Rebecca Nelson, PharmD, BCOP; Dylan Barth, PharmD</i> <i>This activity is sponsored by Stemline.</i>
5:30-6:30 PM Room 122-123	Non-CE Symposium Managing Patients with locally advanced or metastatic KRAS G12C-mutated NSCLC <i>Hatim Husain, MD</i> <i>This activity is sponsored by Amgen.</i>
6:00-8:00 PM Room 118-119	HOPA CAN Help Prevent HIV Community Service Project <i>Pre-registration was required.</i>

Posters and Exhibits	General Session	Commercially Supported Programming	Leadership/Practice Management	BCOP Presentation	Research
----------------------	-----------------	------------------------------------	--------------------------------	-------------------	----------

A = Application-based activity **K** = Knowledge-based activity

SCHEDULE OF EVENTS

All times are Eastern Time.

All session room locations are subject to change, and attendees will be notified of schedule changes via the HOPA mobile app.

Thursday, April 4	
6:15-7:30 AM Bayshore Fitness Trail	5K Fun Run <i>Proceeds benefit HOPA's Research Fund. Pre-registration was required.</i>
7:00-8:00 AM Ballroom Pre-function Area	Attendee Breakfast
7:00-8:00 AM Room 113-117	SIG (Special Interest Groups) Meetings <i>Pediatrics Geriatric Transplant & Cellular Therapy New Practitioner Precision Health in Oncology</i>
7:00-8:00 AM Room 120-121	Non-CE Symposium <i>Key Considerations for Operationalizing Bispecifics in Relapsed or Refractory Multiple Myeloma</i> <i>Kirollos Hanna, PharmD, BCPS, BCOP, FACC</i> <i>This activity is sponsored by Johnson & Johnson Innovative Medicine.</i>
7:00-8:00 AM Room 122-123	Non-CE Symposium <i>Managing Myelofibrosis: A Pharmacist's Perspective</i> <i>Kyle Farina, PharmD, BCPS, BCOP</i> <i>This activity is sponsored by GSK Medical Affairs.</i>
7:00-8:00 AM Room 124-125	Non-CE Symposium <i>Essentials for Pharmacists: A Treatment Option for Relapsed or Refractory Multiple Myeloma From Pfizer</i> <i>Speakers TBD</i> <i>This activity is sponsored by Pfizer.</i>
8:15-9:30 AM Ballroom B-C	BCOP Session 2: CAR T-Cell Breakthroughs in Lymphoma and Myeloma: Balancing Efficacy and Safety (BC2) 1.25 CE A <i>Brian Primeaux, PharmD, BCOP</i>
8:15-9:30 AM Ballroom A	Moving Beyond One Size Fits All for Solid Tumors: Updates in Biomarker Driven Therapies (201) 1.25 CE A <i>Raymond DeMatteo, PharmD, BCOP; Adam Kahleifeh, PharmD, BCOP</i>
9:30-9:40 AM Ballroom Pre-function Area	Break
9:40-10:40 AM Ballroom A	Breakout Session - Rare Malignancies (202) 1.0 CE K <i>To Transplant or Not to Transplant: Current Treatment Approaches for Mantle Cell Lymphoma</i> <i>Michael Buege, PharmD, BCOP</i> <i>Baby Steps: Updates in the Treatment of Infant Leukemia</i> <i>Catherine Martin, PharmD, BCOP</i>
9:40-10:40 AM Ballroom D	Breakout Session - Updates in Medical Oncology (203) 1.0 CE K <i>Advances in Targeted Therapies for Gastrointestinal Malignancies</i> <i>Sarah Chehab, PharmD, BCOP</i> <i>Targeting HER2 Alterations in Patients With Non-Breast/Non-Gastric Cancers</i> <i>Dazhi Liu, PharmD, BCOP</i>
9:40-10:40 AM Ballroom B-C	Breakout Session - Practice Management (204) 1.0 CE A <i>Show Me the Money: Optimizing the Electronic Medical Record (EMR) to Improve Biosimilar Utilization and Pharmacy Reimbursement</i> <i>Nikki Ogle, PharmD, BCOP</i> <i>Cannabinoids and the Oncology Patient: Pearls for Pharmacists</i> <i>Marie Parish, PharmD, BCOP, BCPS</i>
10:40-10:50 AM Ballroom Pre-function Area	Break
10:50-11:50 AM Ballroom B-C	Member Awards and Business Meeting

Posters and Exhibits

General Session

Commercially Supported Programming

Leadership/Practice Management

BCOP Presentation

Research

SCHEDULE OF EVENTS

All times are Eastern Time.

All session room locations are subject to change, and attendees will be notified of schedule changes via the HOPA mobile app.

Thursday, April 4	
11:50 AM-2:15 PM West Hall	Exhibit Hall and Lunch
12:00-1:00 PM Room 120-121	CE Symposium 1.0 CE Elevating Safety and Adherence in Chronic Myeloid Leukemia Through Oncology Pharmacist Expertise Peter Campbell, PharmD, MBA, BCOP; Benyam Muluneh, PharmD, BCOP, CPP; Jordan Snyder, PharmD, BCOP <i>This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.</i>
12:00-1:00 PM Room 122-123	CE Symposium 1.0 CE Advancements in Early-Stage Breast Cancer: The Role of Oncology Pharmacists in Treatment Optimization Danielle Roman, PharmD, BCOP; Allison R. Butts, PharmD, BCOP; Julia Ziegengest, PharmD, BCOP <i>This activity is supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.</i>
12:00-1:00 PM Room 124-125	CE Symposium 1.0 CE What's New in NSCLC Therapies? Key Takeaways for Your Pharmacy Practice Val Adams, PharmD, FCCP, BCOP; Whitney Lewis, PharmD, BCOP <i>This activity is supported by independent educational grants from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC, Regeneron, and Sanofi.</i>
12:00-1:00 PM Room 113-117	SIG (Special Interest Groups) Meetings Gynecologic Oncology Epic (Beacon) Users Administration Academia Specialty Pharmacy
12:00-1:00 PM Room 118-119	Leadership Development Roundtable <i>Attend this roundtable to discuss career ladders and professional development plans</i>
1:00-2:00 PM Ballroom B-C	Annual Advocacy Update Brooke Boring, MPH, CPhT; Jeremy Scott, MA; Lilia Davenport, PharmD, BCPS, BCOP
2:00-2:15 PM Ballroom Pre-function Area	Break
2:15-3:30 PM Ballroom B-C	BCOP Session 3: The Great Financial Debate: Cost vs Margin for Cancer Care Drugs (BC3) 1.25 CE K Chelsee Jensen, PharmD, BCPS, P-RCM; Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA
2:15-3:30 PM Ballroom A	Debating the Incorporation of Novel Therapies in Front-Line Acute Lymphoblastic Leukemia Treatment (205) 1.25 CE K Taylor Kujawa, PharmD; Charlotte Wagner, PharmD, BCOP
3:30-3:45 PM Ballroom Pre-function Area	Break
3:45-4:45 PM Ballroom B-C	BCOP Session 4: Nuances in Neuro-Oncology: Glioma Treatment Advances and New Diagnostic Definitions (BCOP 101) 1.0 CE A Kelly Fritz, PharmD, BCOP
3:45-4:45 PM Ballroom A	New Practitioner's Guide to Navigating Your Career (206) 1.0 CE K Emma Garrison, PharmD; Alison Gulbis, PharmD, BCOP; Matthew Peery, PharmD; Jordan Wallace, PharmD, BCOP
3:45-4:45 PM Ballroom D	REACHing for ROCKstars –iNTEGRATING Updates in Chronic Graft Versus Host Disease (207) 1.0 CE A Shannon Palmer, PharmD, BCOP
4:45-7:30 PM West Hall	Exhibits and E-Poster Reception
5:00-6:00 PM Room 118-119	Diversity + Belonging Reception <i>All are welcome.</i>
5:30-6:30 PM Room 120-121	Non-CE Symposium EMERALD study update: Exploring the safety and efficacy data in patients with ER+/HER2, ESR1-mutated mBC, including data from subgroup analyses Scott Ostriker, PharmD, MBA, BCOP <i>This activity is sponsored by Stemline.</i>

Posters and Exhibits	General Session	Commercially Supported Programming	Leadership/Practice Management	BCOP Presentation	Research
----------------------	-----------------	------------------------------------	--------------------------------	-------------------	----------

A = Application-based activity **K** = Knowledge-based activity

SCHEDULE OF EVENTS

All times are Eastern Time.

All session room locations are subject to change, and attendees will be notified of schedule changes via the HOPA mobile app.

Thursday, April 4	
5:30-6:30 PM Room 122-123	Non-CE Symposium <i>Review of Evidence-Based Data for an Antibody-Drug Conjugate in Combination With a PD-1 Inhibitor for 1L Ia/mUC</i> <i>Sponsored by Pfizer.</i>

Posters and Exhibits

General Session

Commercially Supported Programming

Leadership/Practice Management

BCOP Presentation

Research

SCHEDULE OF EVENTS

All times are Eastern Time.

All session room locations are subject to change, and attendees will be notified of schedule changes via the HOPA mobile app.

Friday, April 5	
6:30-7:30 AM Room 111-112	Yoga <i>Pre-registration was required.</i>
7:00-8:00 AM Room 120-121	CE Symposium 1.0 CE Optimizing JAK Inhibitor Therapy for Myelofibrosis: Insights for Oncology Pharmacists Shawn Griffin, PharmD, BCOP; Amber Clemmons, PharmD, BCOP, FHOPA; James A. Davis PharmD, BCOP <i>This activity is sponsored by MJH Life Sciences™, the parent company of Pharmacy Times® and PTCE.</i>
7:00-8:00 AM Room 122-123	CE Symposium 1.0 CE Optimizing Bispecific Antibody Utilization in Non-Hodgkin Lymphoma: Addressing Challenges in Community-Based Care Sara Moran Smith, PharmD, BCOP; Sarah (Stump) Profitt, PharmD, BCOP; Julio Chavez, MD <i>This activity is supported by an independent medical educational grant from Genmab.</i>
7:00-8:00 AM Room 124-125	CE Symposium 1.0 CE Maximizing Efficacy and Minimizing Toxicity of ADCs Targeting HER2, HER3 and TROP2: Strategies for Oncology Pharmacists Allison Butts, PharmD, BCOP; Sandra Cuellar, PharmD, BCOP, FHOPA, FASHP <i>This activity is sponsored by ProCE, LLC, in partnership with Clinical Care Options, LLC.</i>
7:00-8:00 AM Ballroom Pre-function Area	Attendee Breakfast
7:00-8:00 AM Room 114-117	SIG (Special Interest Groups) Meetings <i>Breast Cancer Ambulatory Industry Professionals Cerner Oncology Users</i>
8:15-9:30 AM Ballroom B-C	BCOP Session 5: Pharmacology and Clinical Application of Complement Inhibitors (BC5) 1.25 CE A <i>Justin Arnall, PharmD, BCOP; Binni Kunvarjee, PharmD, BCOP</i>
8:15-9:30 AM Ballroom A	New Flavors: Bites in Hematologic Malignancies (301) 1.25 CE A <i>Soniya Chandrasekhara, PharmD, BCOP; Shahrier Hossain, PharmD, BCOP; Melissa Royero, PharmD; Kelsea Seago, PharmD, BCOP</i>
9:30-9:40 AM Ballroom Pre-function Area	Break
9:40-10:40 AM Ballroom B-C	Breakout Session - Practical Issues for Clinicians (302) 1.0 CE K Ethical Dilemmas in Oncology Pharmacy: When Science and Morals Collide <i>Karen Fancher, PharmD, BCOP</i> The Gene Therapy Odyssey: Preparing the Pharmacist for New Horizons <i>Abby Kim, PharmD, BCOP</i>
9:40-10:40 AM Ballroom A	Breakout Session - Updates in Hematology Session 303 1.0 CE K Bispecifics in Lymphoma <i>Aseala Abousaud, PharmD, BCOP</i> Taking a Bite Out of Myeloma: The Role of Bi-Specific Antibodies in the Treatment of Relapsed/Refractory Multiple Myeloma <i>Brooke Adams, PharmD, BCOP</i>
9:40-10:40 AM Ballroom D	Breakout Session - Updates in Medical Oncology 304 1.0 CE A Updates in the Management of Endometrial Cancer <i>Emily Graham, PharmD, BCOP, MS</i> Expanding the Use of CDK4/6 Inhibitors to Early-Stage Breast Cancer Treatment <i>Danielle Roman, PharmD, BCOP</i>
10:40-10:50 AM Ballroom Pre-function Area	Break
10:50- 11:50 AM Ballroom B-C	John G. Kuhn Keynote Address: Dr. Glaucomflecken – Wife & Death & Comedy (non-CE) <i>William Flanary, MD</i>
11:50 AM-2:15 PM West Hall	Exhibits, Trainee Research Posters and Lunch

Posters and Exhibits	General Session	Commercially Supported Programming	Leadership/Practice Management	BCOP Presentation	Research
----------------------	-----------------	------------------------------------	--------------------------------	-------------------	----------

A = Application-based activity **K** = Knowledge-based activity

SCHEDULE OF EVENTS

All times are Eastern Time.

All session room locations are subject to change, and attendees will be notified of schedule changes via the HOPA mobile app.

Friday, April 5	
12:00-1:00 PM Room 114-117	SIG (Special Interest Groups) Meetings <i>Classical Hematology</i> <i>Trainee</i> <i>Investigational Drug Services (IDS)</i> <i>Residency Program Directors</i>
12:00-1:00 PM Room 120-121	Non-CE Symposium <i>Understanding the role of pharmacists in the management of Low-risk Myelodysplastic Syndromes (MDS)</i> David Sallman, MD; Katie Tobon, Pharm D, BCOP <i>This activity is sponsored by Bristol Myers Squibb.</i>
12:00-1:00 PM Room 122-123	Non-CE Symposium <i>Practical Management of AML with a BCL-2 Inhibitor</i> <i>This activity is sponsored by AbbVie.</i>
12:00-1:00 PM Room 124-125	Non-CE Symposium <i>Explore the current data that could help you recognize/assess candidates for a CDK4 & 6 inhibitor.</i> Rodney J. Hunter, PharmD, BCOP <i>This activity is sponsored by Eli Lilly and Company.</i>
2:15-3:00 PM Ballroom B-C	Incoming President's Remarks Jolynn K. Sessions, PharmD, BCOP, FHOPA
3:00-3:15 PM Ballroom Pre-function Area	Break
3:15-4:15 PM Ballroom B-C	BCOP Session 6: Aiming for the Bullseye: Updates in Pediatric Solid Tumor Precision Medicine (BC6) 10CE A Tara Higgins, PharmD, BCPPS, FPPA, FFSHP
3:15-4:15 PM Ballroom A	Buzzworthy Bladder Breakthroughs: Updates in Metastatic Bladder Cancer (305) 10CE K Kelly Brunk, PharmD, BCOP
6:00-9:00 PM Riverwalk near the Convention Center	HOPA's 20th Anniversary Celebration on the Yacht Starship <i>Pre-registration was required for this fee event.</i>

Posters and Exhibits

General Session

Commercially Supported Programming

Leadership/Practice Management

BCOP Presentation

Research

SCHEDULE OF EVENTS

All times are Eastern Time.

All session room locations are subject to change, and attendees will be notified of schedule changes via the HOPA mobile app.

Saturday, April 6	
7:00-8:00 AM Room 120-121	CE Symposium 1.0 CE New Frontiers in the Treatment of Lower-Risk Myelodysplastic Syndromes (LR-MDS): Bridging Clinical Innovation and Practice Anthony Perissinotti, PharmD, BCOP; Firas El Chaer, MD; Rachel Feaster, PharmD, BCOP, BCPS This activity is supported by educational grants from Geron Corporation and Bristol Myers Squibb.
7:00-8:00 AM Room 122-123	CE Symposium 1.0 CE Enhancing Bruton Tyrosine Kinase Inhibitor Outcomes in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: A Pharmacist's Roadmap to Success Karen M. Fancher, PharmD, BCOP; Melanie A. Rudisill, PharmD, BCOP; Alison Duffy PharmD, BCOP This activity is supported by an educational grant from Lilly.
7:00-8:00 AM Ballroom Pre-function Area	Attendee Breakfast
8:15-9:15 AM Ballroom B-C	BCOP Session 7: Up to My Neck (In Head and Neck Cancer Updates) (BC7) 1.0 CE K Christine Barrett, PharmD, BCOP
8:15-9:15 AM Ballroom A	Clinical Pearls (401) 1.0 CE K Challenging the Recognition and Treatment Management for HER2-low Breast Cancer Megan May, PharmD, BCOP, FHOPA, FAPO Best Practices – Management of Alpelisib-Induced Hyperglycemia Marie Sirek, PharmD, BCACP, CPP Metastatic Castrate Resistant Prostate Cancer in a State of (Homologous Recombination) Repair: Navigating PARPi Therapy Selection Mary Walters, PharmD, BCOP
9:15-9:25 AM Ballroom Pre-function Area	Break
9:25-10:25 AM Ballroom B-C	To Treat or Not To Treat? The Role of Immunotherapy in Non Small Cell Lung Cancer (NSCLC) With Oncogenic Drivers (402) 1.0 CE A Leila Rostamjad, PharmD, BCOP; Mya Tran, PharmD, BCOP
9:25-10:25 AM Ballroom A	Research Grant Award Presentations (403) 1.0 CE A Oncology Pharmacist-Driven Symptom Monitoring System Uncovered Health Disparities in Minoritized Patients Receiving Anticancer Therapies Alexandre Chan, BCOP, BCPS, FISOPP Pharmacist Monitoring of Patient-Reported Outcome Measures (PROMs) for Oral Oncolytics Debbie Liang, PharmD, BCCCP; Angela Stover, PhD
9:25-10:25 AM Ballroom D	Updates in Chronic Lymphocytic Leukemia: Sequencing Versus Combination Therapy of Small Molecule Inhibitors (404) 1.0 CE A Clement Chung, PharmD, BCOP, MS, BCPS
10:25-11:35 AM Ballroom Pre-function Area	Break
10:35-11:35 AM Ballroom B-C	Igniting Breakthroughs in Pharmacogenetics & Genomics: Unveiling the Pathogenic Potential of VUS Through DEI Enhancement (405) 1.0 CE A Porscha Johnson, PharmD, CPGx
10:35-11:35 AM Ballroom A	Collaborative Practice in Clinical Trials: Reinforcements for the Crisis in Clinical Research (406) 1.0 CE K Jennifer Espiritu, PharmD, BCOP, CCRP
11:45 AM-12:45 PM Room 120-121	Non-CE Symposium Long-Term Clinical Trial Results for a BTKi in the Treatment of CLL/SLL Mark Wagner, PharmD This activity is sponsored by AstraZeneca.
11:45 AM-12:45 PM Room 122-123	Non-CE Symposium Harnessing the Power of Human Immunity Greg Eskinazi, RPh, BCOP, CCRP This activity is sponsored by Regeneron.

Posters and Exhibits	General Session	Commercially Supported Programming	Leadership/Practice Management	BCOP Presentation	Research
----------------------	-----------------	------------------------------------	--------------------------------	-------------------	----------

A = Application-based activity **K** = Knowledge-based activity

2024 BOARD OF DIRECTORS UPDATE

Please join HOPA as we welcome our newly elected officials!



President-Elect

Robert Mancini, PharmD, BCOP, FHOPA
St. Luke's Cancer Institute & Idaho State University



Secretary

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA
University of Kansas Cancer Center



At-Large Member

Kamakshi Rao, PharmD, BCOP, FHOPA
University of North Carolina Medical Center

Please welcome our new HOPA leaders with your applause during the Member Business Meeting and Awards on Thursday, April 4 at 10:50-11:50 a.m. ET.

CLASS OF 2024 HOPA FELLOWS

HOPA recognizes these distinguished members for their excellence in oncology pharmacy and sustained contributions to HOPA. Congratulations!



**Lindsey Amerine, PharmD, MS,
BCPS, CPEL, FASHP, FHOPA**
Cleveland Clinic



**Joseph Bubalo, PharmD, BCPS,
BCOP, FHOPA**
Oregon Health & Science University
Hospital



**Larry W. Buie, PharmD, BCOP,
FCCP, FASHP, FHOPA**
Daiichi Sankyo, Inc.



**Sara S. Kim, BS, PharmD, BCOP,
FHOPA**
Northwell Health Cancer Institute



**Chung-Shien Lee, PharmD, BCPS,
BCOP, FHOPA**
St. John's University College of
Pharmacy and Health Sciences &
Northwell Health Cancer Institute



**Benyam Muluneh, PharmD, BCOP,
FHOPA**
UNC Eshelman School of Pharmacy



**Kate Deen Taucher, PharmD, MHA,
BCOP, FHOPA**
UC Health Memorial Hospital

Show your support by attending the President's Welcome and Recognition of 2024 HOPA Fellows on Wednesday, April 3 at 2:45-3:30 p.m. ET.

2024 MEMBER AWARDS WINNERS

Congratulations to these HOPA members who have shown outstanding achievement in their field.



Onyebuchi Ononogbu, PharmD, BCOP
Diversity, Equity and Inclusion Award
*University of Houston & UT Physicians
Comprehensive Sickle Cell Center*



Heather Cranford, CPhT
Hematology/Oncology Pharmacy
Technician Award
*Atrium Health Specialty Pharmacy
Service*



Julie Kennerly-Shah, PharmD, MS, MHA, BCPS
Leadership Award
*The Ohio State University Wexner
Medical Center*



Lisa M. Holle, PharmD, BCOP, FHOPA, FISOPP
Mentorship Award
*UConn School of Pharmacy &
UConn Health Carole and Ray Neag
Comprehensive Cancer Center*



Becky Fahrenbruch, PharmD, BCOP, FHOPA
Mentorship Award
Genmab



Benjamin Andrick, PharmD, BCOP
New Practitioner Award
Geisinger

*Congratulate your colleagues when you attend the Member Business Meeting and Awards on
Thursday, April 4 at 10:50-11:50 a.m. ET.*

2024 MEMBERS AWARD WINNERS

Congratulations to these HOPA members who have shown outstanding achievement in their field.



Kayleigh R. Marx, PharmD, BCOP
Outstanding Clinician Award
MD Anderson Cancer Center



Stephen J. Lirette, PharmD, BCOP
Patient Advocacy Award
*University of Alabama at Birmingham
Medicine*



**Shawn Patrick Griffin, PharmD,
BCOP**
Volunteer Award
*UCI School of Pharmacy &
Pharmaceutical Sciences*



**Alexandre Chan PharmD, MPH,
FCCP, FISOPP, BCPS, BCOP, APH**
Basic Science and Clinical Research
Literature Award
*UCI School of Pharmacy &
Pharmaceutical Sciences*



Melissa Carroll, PharmD, BCPS
Oncology Pharmacy Practice Literature
Award
McKesson/US Oncology Network

*Cheer on your colleagues when you attend the Member Business Meeting and Awards on
Thursday, April 4 at 10:50-11:50 a.m. ET.*

ONCOLOGY
PHARMACISTS
CONNECT
SUMMER 2024

10+ LIVE CE CREDITS
and HOPA's Curated BCOP
Program available!

JUNE 20-21, 2024
Sheraton Austin Hotel at the Capitol
Austin, Texas



SCAN TO
REGISTER



Oncology Pharmacists Connect: Summer 2024 promises to be an immersive experience for professionals seeking not just growth but excellence in the ever evolving health care landscape. Join thought leaders and decision makers in oncology pharmacy to discuss recently presented data reported at the ASCO annual meeting!

Following **Summer Connect 2024**, HOPA will be hosting a Curated BCOP Program, featuring a minimum of 4.25 BCOP CE hours from Practice Management, Annual Conference, and BCOP Updates to present some of the most sought-after BCOP CEs this year.

**HOPA members save 30% off
Connect registration: MEMBER30**



In partnership with:



BE PART OF HOPA'S **GROWING** AND **IMPACTFUL** COMMUNITY

Gain the tools and confidence you need to provide the best possible patient care through your membership with HOPA.



Find out more at hoparx.org/membership.



LILLY FOR BETTER LIVES

Our work extends beyond the medicines we create. Together, we're working to improve health and access to life-saving medicines in our local communities and around the globe. Through partnerships and our signature volunteer programs, we aim to identify and promote successful solutions to health issues that can be scaled and replicated to make life better for people here at home and around the world.

Learn more about our commitment to local communities and people everywhere at lilly.com.



CONTINUING PHARMACY EDUCATION

Conference Objectives

By participating in HOPA Annual Conference 2024, attendee will increase their ability to

- describe current controversies relating to the screening and treatment of patients with solid tumors and hematologic malignancies
- apply new and emerging therapies for hematology and oncology patients to clinical practice
- interpret recent developments in the medical literature regarding hematology/oncology medications

Mission

The purpose of the Hematology/Oncology Pharmacy Association's Continuing Pharmacy Education (CPE) Program is to provide members with opportunities for lifelong learning and assistance in fulfilling their maintenance of certification and licensure requirements, thereby promoting excellence in the provision of pharmacy care.

Definition of Continuing Pharmacy Education

Continuing education for those in the profession of pharmacy is a structured educational activity designed or intended to support the continuing development of pharmacists and pharmacy technicians to maintain and enhance their competence. CPE should promote problem solving and critical thinking and be applicable to the safe practice of pharmacy.

Source: www.acpe-accredit.org

Definition of Commercial Interest

A commercial interest is any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by, or used on, patients. Providers of clinical service directly to patients are not commercial interests.

Source: www.acpe-accredit.org

Learner's Bill of Rights

HOPA recognizes that you are a lifelong learner who has chosen to engage in CPE to identify or fill a gap in knowledge or skill, and to attain or enhance a desired competency. You have the right to expect that, as part of HOPA's fulfillment of its duties to you as a learner, your CPE experience with HOPA will include the following:

Content that

- promotes improvements or quality in health care
- is current, valid, reliable, accurate, and evidence-based
- addresses the stated objectives or purpose and is driven by and based on an independent survey and analysis of learners' needs, not commercial interests
- has been reviewed for scientific rigor
- offers balanced presentations that are free of commercial bias
- is vetted through a process that resolves any conflicts of interest of planners and faculty
- is evaluated for its effectiveness in meeting the identified educational need

A learning environment that

- is based on adult learning principles that support the use of various modalities
- supports learners' abilities to meet their individual needs
- respects and attends to any special needs of the learners
- respects the diversity of groups of learners
- is free of promotional, commercial, and sales activities

Disclosure of

- relevant financial relationships that planners, teachers, and authors have with commercial interests related to the content of the activity
- commercial support (funding or in-kind resources) of this activity

CONTINUING PHARMACY EDUCATION

Independence in CPE

The mission of HOPA's CPE program is to improve patient care and healthcare outcomes by maintaining, developing, and enhancing medical knowledge, patient care, interpersonal and communication skills, and professionalism. As a provider accredited by the Accreditation Council for Pharmacy Education (ACPE) and in support of this mission, HOPA is dedicated to providing CPE that is independent, fair, balanced, objective, and free of commercial bias. HOPA employs several strategies to ensure that these standards will be met. HOPA's Annual Conference Committee members submit and consider their own disclosure information and recuse themselves from planning educational activities if they have conflicts related to the subject area covered. When developing an educational program, the committee reviews applications and conflict-of-interest disclosures, along with needs assessment and evaluative data from past activities. Potential participants are sent detailed guidelines on components necessary to ensure independence in CPE activities and to resolve conflicts, as itemized below.

Statement of Need and Program Overview

HOPA organizes an Annual Conference for hematology/oncology pharmacy practitioners to educate attendees about emerging research, new treatment regimens, clinical updates on treatment of tumor types, new supportive care therapies, and common clinical and technical issues in the hematology/oncology clinical setting.

The overall goal of educating oncology pharmacy practitioners about current developments is to improve the efficiency of healthcare delivery while maintaining or increasing the quality of patient care. Hematology/oncology practitioners who have been informed about the latest developments in clinical trials, therapeutic regimens, treatment guidelines, and emerging technologies, will be well-positioned to participate in clinical decision-making and healthcare initiatives that have a direct and positive impact on care management for cancer patients. Objectives of the 2024 HOPA Annual Conference include educating attendees about topics of emerging interest in care management for cancer patients and practical issues that pharmacists face while delivering cancer care. Decisions about topics, scheduling, venue, and speakers for HOPA Annual Conference are made on the basis of therapeutic advances in hematology/oncology, current medical news, input from various HOPA planning committees, and suggestions from members and past conference attendees.

Target Audiences

The primary target audience of the HOPA Annual Conference is its pharmacist members. Secondary audiences are pharmacy residents and other pharmacy healthcare professionals.

Disclosure of Conflicts of Interest

HOPA assesses conflicts of interest with its faculty, planners, managers, and other individuals who are in a position to control the content of CPE activities. All identified potential conflicts of interest are thoroughly reviewed, with consideration given to balance, scientific objectivity of studies used in the activity, and recommendations for patient care. HOPA is committed to providing its learners with high quality CPE activities and related materials that promote improvements and/or quality in healthcare, and not specific proprietary commercial interests.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published or investigational uses of agents that are not indicated by the U.S. Food and Drug Administration. HOPA and its faculty, planners, managers, and commercial supporters do not recommend the use of any agent outside the labeled indications. The opinions expressed in the educational activities are those of the faculty and do not necessarily represent the views of HOPA or any other organizational or commercial entities.

Resolution of Conflicts of Interest

In accordance with the ACPE Standards for Commercial Support of CPE, the Hematology/Oncology Pharmacy Association has, prior to the planning and implementation of this CPE activity, implemented mechanisms to identify and mitigate conflicts of interest for all individuals in a position to control the content of this CPE activity. To view a list of all speaker and planner disclosures, refer to the conference website.

Hematology/Oncology Pharmacy Association Accreditation Statement

The Hematology/Oncology Pharmacy Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

CONTINUING PHARMACY EDUCATION

Credit Designation


The Hematology/Oncology Pharmacy Association is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of all Annual Conference programming can provide up to approximately 35 credits. Successful completion includes participating in all session activities and completing online session assessments and evaluations. A statement of participation will be available online shortly following successful completion of the CE activity.

The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of Board Certified Oncology Pharmacist (BCOP) credit. A BCOP statement of credit will be issued only upon successful completion of a post-test with a passing grade of 75% achievement, and a session evaluation form.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in these activities is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in these activities should not be used by clinicians without evaluation of their patients' conditions and possible contraindications because of dangers in their use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

6 Easy Steps to Claim Your HOPA2024 CE Credits*



01. Log In

As a registered attendee, log in to your HOPA Learn account at: <https://learn.hoparx.org/>



02. Click!

Click on "2024 HOPA Annual Conference (Live)" which will appear in your list of courses.

03. Take the Pre-Test

You may have taken the pre-test in advance. If not, you'll need to take it now in order to proceed.



04. Attend HOPA2024 Session(s)

Attendance will be verified by entering a unique code provided in the presentation slides.



05. Take the Post-Test and Evaluation



SUBMIT

06. Hit "Submit!"

*In May, 2024, sessions missed live by HOPA2024 registrants will automatically become available on demand, at no added cost.

CONTINUING PHARMACY EDUCATION

Accreditation Council for Pharmacy Education (ACPE) Credits

To claim live Accreditation Council for Pharmacy Education (ACPE) credit, attendees must complete the following for each session:

- pre-test
- attend and engage in the session and discussion
- input of session code (for live credit only)
- post-test
- session evaluation

Audience response polling questions will be available during the session by using your smart device camera and scanning a QR code that will display on the slides during the live session. The pre-test, code entry, post-test and session evaluation can be found online in HOPA Learn at www.learn.hoparx.org. The pre-test will be made available in advance and should be taken before the session. The post-test and session evaluation should be taken after the session, by the Live Credit Claim date listed below. The BCOP sessions are available to all conference attendees for ACPE credit as well.

Live Credit Claim Deadline (ACPE and BCOP)

Monday, May 20, 2024

In accordance with the pharmacy credit reporting program of the National Association of Boards of Pharmacy (NABP), participants have 45 days after the completion of each session to submit an evaluation and claim credit for the activity.

Please note: HOPA can only transfer credits to ACPE through the date above. After this time, HOPA will charge a \$200 fee to transfer credits to ACPE. **You have 45 days to claim live credit for a course that you attended during the conference. Please check your NABP profile to ensure that the credits are reflected on your account within 7 days after the 45-day deadline. If your credits are not on your NABP profile at that time, you will not be able to claim live credit for that course.** (The same applies for the Live BCOP credits referenced below).

On-Demand Sessions: About five to six weeks after the conference, attendees will see the On-Demand version of the Annual Conference on their HOPA Learn dashboard. This is where the on-demand sessions from the conference will be available for credit for one year, until Wednesday, May 21, 2025

Board Certified Oncology Pharmacist (BCOP) Recertification Credits

Board Certified Oncology Pharmacist (BCOP) credit will be issued for individual live BCOP sessions. To claim live BCOP credits, attendees must complete the following for each session:

- pre-test
- attend and engage in the session and discussion
- input of session code (for live credit only)
- post-test
- BCOP Recertification questions
- session evaluation

Audience response polling questions will be available during the session by using your smart device camera and scanning a QR code that will display on the slides during the live session. The pre-test, code entry, post-test and session evaluation can be found online in HOPA Learn at www.learn.hoparx.org.

The pre-test will be made available in advance and should be taken before the session. The post-test and session evaluation should be taken after the session, by the end of each conference day. To earn BCOP credits, attendees must earn a score of 75% or better on the BCOP Recertification test. Live credits must be claimed within the same deadlines listed in the "Live Credit Claim Deadline," section, to the left.

On-Demand Sessions: About five to six weeks after the conference, attendees will see the On-Demand version of the Annual Conference on their HOPA Learn dashboard. This is where the on-demand sessions from the conference will be available for credit for one year, until Wednesday, May 21, 2025. HOPA will send notification of earned BCOP recertification credits to the Board of Pharmacy Specialties.

Please be aware that you will only be able to claim credit for either the live or on-demand version of any given course.

Changes to the Conference Schedule

Speakers, topics and rooms are subject to change. Check the conference website and mobile app for the most up-to-date information.

Thanks to HOPA's Educational Supporters

HOPA thanks the unrestricted educational grantor for their support of the HOPA Annual Conference 2024:

AstraZeneca Pharmaceuticals

GENERAL INFORMATION

Americans with Disabilities Act

HOPA staff will be glad to assist you with any special needs. Please visit the on-site registration desk, or contact the HOPA Team at events@hoparx.org, for special assistance.

Privacy Statement

The Hematology/Oncology Pharmacy Association (HOPA) has a strong commitment to privacy, recognizing that we are a public association. HOPA's Privacy Statement outlines the policies and procedures concerning information gathering and dissemination practices for our organization. This privacy statement can be found on the HOPA website: <https://www.hoparx.org/about-us/hopa-policies-disclaimers/>. If you have any questions, please contact HOPA at events@hoparx.org.

Photography and Video Recording Policy

Photography, video or audio recording of these sessions, materials, speakers, and HOPA graphics without written permission from HOPA is strictly prohibited.

Please note that photographs, video and audio recording taken by or on behalf of HOPA shall be property of HOPA, and may be used in future HOPA publications or on the HOPA website.

Organization Names and Logos

The HOPA name, logo, and acronym may not be used in any mailing pieces, signs, advertising, or promotions in any media, either inside or outside of the meeting hotel, before, during, or after the meeting without prior review and approval by HOPA.

Embargo Policy

HOPA's embargo policy states that coverage of abstracts being presented at the annual conference is strictly prohibited until 2 weeks before the conference. Content that is prepublished online, in advance of print publication, is still subject to HOPA's embargo policy.

Publication of Proceedings

Publishing (in either print or electronic media) the description of, or information about, any session held at HOPA Annual Conference 2024 is not permitted unless and until it has been reviewed and approved by HOPA. Note that HOPA retains all publication rights to descriptions of, and proceedings from, this conference, including the right to refuse any entities permission to publish such materials, as HOPA sees fit.

Nursing Mother's Room

A secured room equipped with power and a refrigerator is available. Please visit the HOPA registration desk to obtain the key code. Also, during times when a reception is being held in the Exhibit Hall, please stop by the HOPA booth for the code.

Mobile App

Our mobile app will help you navigate and plan your perfect conference experience. As a registered attendee, simply download the HOPA Events app on your iPhone or Android device and follow these instructions:

1. Go to your app store and search for **HOPA Events**
2. Enter the app for easy setup
3. Navigate the app for all conference information, to personalize your schedule, access all poster presentations, and view the exhibit hall interactive map

Wellness Statement

As a healthcare organization, it is vital that all attendees present at HOPA's in-person meetings are not at risk of their health and well-being being affected.

In order to ensure this, we rely upon all attendees to do their part. If you feel sick, please use your best judgement, and consider the best course of action, which may require you to stay at home or seek medical advice. If you see others choosing to wear facemasks, please be respectful of their choices.

If you are attending a HOPA event and are experiencing symptoms of COVID-19, please notify HOPA Staff via email at events@hoparx.org

HOPA thanks you in advance for your attention to your personal health and well-being, as well as the personal health and well-being of other HOPA meeting attendees.



FOTIVDA[®]
(tivozanib) capsules

See what this means
for your patients.




Go to **FOTIVDA.com** or scan the code



TAMPA CONVENTION CENTER MAP




TAMPA CONVENTION CENTER MAP



FLOOR PLAN LEGEND	
	Automatic External Defibrillator
	Business Center
	Cafés, Concessions & Restaurants
	Administrative Offices
	Family Restrooms
	First Aid
	Floor Ports
	Main Entrances
	Men's Restrooms
	Pillar
	Women's Restrooms





ENGINEERING THE NEXT GENERATION OF HIGH-QUALITY AND ACCESSIBLE MEDICINES

Global footprint. Local impact. Access driven.

At BeiGene, we let our passion for innovation and value lead us forward,
one clinical trial at a time.

LEARN MORE ABOUT BEIGENE'S PORTFOLIO AT [BEIGENE.COM](https://www.beigene.com)



SCHEDULE FOR EXHIBITS AND POSTERS

Exhibits and Posters are in the West Hall.

Stop by the Exhibit Hall and participate in the Scavenger Hunt. It's a great way to break the ice with booth representatives.

Wednesday, April 3

4:45 – 7:00 p.m. Welcome Reception: Exhibits and Industry Encore Posters

Thursday, April 4

11:50 a.m. – 2:15 p.m. Exhibits*

4:45 – 7:30 p.m. Exhibits and E-Poster Reception

Friday, April 5

11:50 a.m. – 2:15 p.m. Trainee Posters and Exhibits*

*Lunch will also be available at these times in the West Hall.

DISCOVER THE
**EFFICACY
& SAFETY**
OF

QINLOCK[®]
(riporetinib) 50 mg tablets

VISIT
QINLOCKHCP.COM

© 2023 Deciphera Pharmaceuticals. QINLOCK and the QINLOCK logo are registered trademarks of Deciphera Pharmaceuticals, LLC. All rights reserved. DCPH-P0128110/23

Amneal is growing in the oncology market

Alymsys
(bevacizumab-maly)

Fylnetra
(pegfilgrastim-pbbk)

Releuko
(filgrastim-ayow)

In 2022 Amneal entered the US biosimilars market with the FDA approval of 3 key oncology products: ALYMSYS®, FYLNETRA®, and RELEUKO®. With the approval of PEMRYDI RTU™ (pemetrexed injection) in May 2023, we continue to expand our Biosciences Oncology portfolio.¹⁻⁴

PEMRYDI RTU™
(pemetrexed injection)

At Amneal, we believe that medicine should be available to the patients who need it most. That is why we are committed to deepening our biosciences capabilities by prioritizing the development of **biosimilars** and **new formulations** of foundational therapies. We have brought **over 270 products** to the market in the last **20 years** thanks to our streamlined manufacturing and dedicated field force.^{5,6} We plan to continue to use these capabilities to **further invest in the oncology space** and expand our pipeline in the coming years.



Learn about our PATHways® patient support program

Look to the Amneal PATHways program's full suite of services to help you deliver the best care possible, to every patient. Please scan QR code to learn more.

References: **1.** ALYMSYS. Package insert. Amneal Pharmaceuticals LLC; 2022. **2.** FYLNETRA. Package insert. Amneal Pharmaceuticals LLC; 2022. **3.** RELEUKO. Package insert. Amneal Pharmaceuticals LLC; 2022. **4.** Amneal Pharmaceuticals LLC [press release]. June 14, 2023. Accessed September 5, 2023. <https://investors.amneal.com/news/press-releases/press-release-details/2023/Amneal-Receives-505b2-NDA-Approval-from-FDA-for-PEMRYDI-RTU-a-Ready-to-Use-Oncology-Injectable/default.aspx> **5.** Amneal Pharmaceuticals LLC. Our portfolio. Accessed September 15, 2023. <https://amneal.com/products/our-portfolio/> **6.** Amneal Pharmaceuticals LLC. Generic products. Accessed September 15, 2023. <https://amneal.com/products/our-portfolio/generic-products/>

Thanks to our exhibitors for participating in the HOPA Annual Conference 2024.*

AbbVie, Booth 201 **IRC** **Titanium Sponsor**

abbvie.com/oncology

At AbbVie, we are committed to transforming standards of care for blood cancers while advancing a dynamic pipeline of investigational therapies across many cancer types. Our dedicated team joins forces with innovative partners to accelerate the delivery of potentially breakthrough medicines for patients. We are evaluating more than 20 investigational medicines in over 300 clinical trials across some of the most debilitating cancers. For more details, please visit <http://www.abbvie.com/oncology>.

Acrotech Biopharma, Inc, Booth 318

acrotechbiopharma.com

Founded in 2018, Acrotech Biopharma, Inc, was formed as a global platform to commercialize innovative proprietary medications. The company aims to launch scientifically advanced products to address unmet needs and deliver value to patients as well as all healthcare stakeholders. Acrotech aspires to be a patient focused, research-based organization that strives to launch treatments which are accessible to patients that need them.

American Regent, Booth 408

americanregent.com

For more than 50 years, American Regent, Inc., a Daiichi Sankyo Group company, has been developing, manufacturing and supplying quality generic and branded injectables. As a top-10 injectable manufacturer, we understand the importance of ensuring consistent supply of our products. As a result, American Regent is committed to US based manufacturing. Speed counts. Flexibility matters. Reliability and quality are paramount. Because patients should never have to wait for the medications they need.

Amgen, Booth 506 **IRC**

amgen.com

While science continues to explore potential cures, every cancer journey is full of challenges from many angles. We can do more. Amgen Oncology advances All Angles of Care by delivering a spectrum of cancer treatment options, from transformative medicines to outcome-enabling solutions such as supportive care and biosimilars.

Amneal Pharmaceuticals, Booth 409 **Gold Sponsor**

amneal.com

Amneal Pharmaceuticals, Inc. is a U.S specialty pharmaceutical company focused on developing, manufacturing and distributing a growing portfolio of generic, complex generic – including biosimilars - and branded products. Our colleagues deliver Quality and value for customers and patients primarily within the United States. Visit Amneal.com for more information.

Apellis Pharmaceuticals, Booth 209

apellis.com

Apellis is a global biopharmaceutical company that leverages courageous science and creativity. We are committed to addressing the unmet needs of patients and eye care professionals worldwide.

Astellas, Booth 310 **IRC**

astellas.com/us

Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients and their families. Keeping our focus on addressing unmet medical needs and conducting our business with ethics and integrity enables us to improve the health of people throughout the U.S. and around the world.

AstraZeneca, Booth 301 **IRC** **Platinum Sponsor**

astrazeneca-us.com

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Please visit astrazeneca-us.com for more information.

AVEO Oncology an LG Chem Company, Booth 314 **IRC**

FOTIVDAHCP.com

AVEO Oncology (“AVEO”) is an oncology-focused biopharmaceutical company committed to providing innovative solutions to improve cancer patients' lives. On January 19, 2023, AVEO was acquired by LG Chem, Ltd. (“LG Chem”), establishing a U.S. commercial presence for LG Chem and expanding LG Chem's global oncology portfolio. AVEO continues to commercialize FOTIVDA® (tivozanib) in the U.S. To learn more about FOTIVDA efficacy, safety, and relevant resources, visit FOTIVDAHCP.com.

*As of February 15, 2024

EXHIBITORS

BD, Booth 614

bd.com/en-us

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. bd.com

BeiGene, Booth 407

IRC

Gold Sponsor

beigene.com

BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 9,000+ employees around the world are committed to expediting the development of a diverse pipeline of novel therapeutics.

BPS, Booth 621

BTG Pharmaceuticals, Booth 521

serb.com

BTG Pharmaceuticals, a SERB company, is dedicated to helping healthcare providers treat patients with critical conditions, focusing on emergency care and rare diseases. For over 30 years we have helped treat complex and life-threatening conditions; supporting clinicians, healthcare systems and governments while offering hope to patients.

CLL Society, Booth 316

cllsociety.org

CLL Society is a nonprofit organization that addresses the unmet needs of the chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) community through patient education, policy/advocacy work, free support services, and funding research.

CVS Specialty, Booth 708

cvsspecialty.com

Personalized Specialty Pharmacy Services Our commitment to helping patients and their physicians manage complex drug therapies by delivering individualized patient care with compassion and dedication has made us one of the leading specialty pharmacies in the country. To learn more or to enroll patients, call 1-800-238-7828.

Daiichi Sankyo, Inc., Booth 613

IRC

dsi.com

With more than 120 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.

Daiichi Sankyo, Inc., Booth 513

IRC

daiichisankyo.us

Daiichi Sankyo, Inc., the U.S. subsidiary of Daiichi Sankyo Co., Ltd., is headquartered in Basking Ridge, New Jersey, and is focused on the development and delivery of oncology and specialty medicines.

Deciphera Pharmaceuticals, Booth 718

deciphera.com

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines.

Eitan Medical, Booth 512

eitanmedical.com

Eitan Medical is reimagining drug delivery, with reliable innovations that put patients at the center of care, making drug delivery easier and safer than ever before. Patient safety and care are only the starting point, as Eitan Medical goes beyond- delivering connected, intuitive drug delivery and infusion solutions that are designed to improve patient and clinician quality of life across the continuum of care, including pre-acute, hospital, ambulatory, and home care environments.

Eli Lilly and Company, Booth 413

IRC

Silver Sponsor

lilly.com

Lilly unites caring with discovery to create medicines that make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 47million people across the globe. To learn more, visit lilly.com and lilly.com/newsroom.

Equashield LLC, Booth 313

equashield.com

EQUASHIELD is a leading provider of manual and automated solutions for hazardous drug handling. The EQUASHIELD CSTD covers more routes of exposure than alternative systems with its unique closed-back Syringe Unit. Together, the EQUASHIELD CSTD and Mundus Mini HD redefine handling hazardous drugs by reducing the risk of exposure, minimizing medication errors, and simplifying workflows.

Exelixis, Booth 523 IRC

exelixis.com

Founded in 1994, Exelixis is a biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines. Visit our website to learn more. www.exelixis.com

Fennec Pharmaceuticals, Booth 321

fennecpharma.com

Fennec Pharma is committed to helping children at risk of hearing loss due to ototoxicity. Young children are especially vulnerable to the ototoxic effects of cisplatin-based chemotherapy because their ears are still developing. The impact of ototoxicity may be permanent, severe, and profound—with the potential to significantly impair cognitive performance and the development of social and language skills.

Genentech, A Member of the Roche Group, Booth 323

IRC

gene.com

Genentech pioneered the biotech industry and continues to pursue revolutionary science and develop life-changing medicines to treat some of the world's most complex health problems. Learn more at gene.com.

Gilead Sciences, Inc., Booth 517 IRC

gilead.com

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

GSK, Booth 619 IRC

Gold Sponsor

<http://us.gsk.com/en-us>

Hematology/Oncology Pharmacy Association, Booth 417

hoparx.org

The Hematology/Oncology Pharmacy Association (HOPA) serves more than 3,600 members made up of pharmacists, pharmacy residents, students, and technicians specializing in hematology/oncology practice. HOPA's mission is to support practitioners, and promote and advance hematology/oncology pharmacy to optimize the care of individuals affected by cancer. Our events and educational programs equip oncology pharmacy practitioners with knowledge about developments in the field of oncology pharmacy to improve the efficiency of healthcare delivery.

Immunogen, Booth 616 IRC

Incyte, Booth 511 IRC

incyte.com

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte [[twitter.com](https://twitter.com/Incyte)].

Infusystem, Booth 612

infusystem.com

InfuSystem is the leading national provider of ambulatory infusion pumps, supplies and biomedical services to oncology clinics and other outpatient infusion centers. Our comprehensive Oncology program is uniquely designed to elevate the standard of patient care from the clinic to the home. InfuSystem's team of compassionate and knowledgeable Registered Nurses (RN) provides continuous patient support 24/7, assisting patients every step of the way.

JADPRO/APSHO, Booth 608

apsho.org

APSHO is a 501(c)6 nonprofit membership organization consisting of nurse practitioners, physician assistants, pharmacists, clinical nurse specialists, and advanced practice nurses, all working in oncology. A Board of Directors manages APSHO and its business is conducted by various committees comprising APSHO member volunteers. It's supported by APSHO's management company, Harborside-BroadcastMed.

EXHIBITORS

Johnson & Johnson, Booth 319 **IRC**

jnj.com

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.

Karyopharm Therapeutics Inc., Booth 609

karyopharm.com

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of novel first-in-class drugs for the treatment of cancer and other diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1.

Merck & Co., Inc., Booth 401 **IRC**

merck.com

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we've been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world's most challenging diseases.

Mirati – A Bristol Myers Squibb company, Booth 607

IRC

Novartis Pharmaceuticals Corporation, Booth 501

IRC

novartis.com

Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development.

Pfizer Oncology, Booth 320 **IRC**

pfizer.com

Pfizer Oncology is at the forefront of a new era in cancer care. Driven by science, we are committed to accelerating breakthroughs to extend and improve the lives of people living with some of the world's most common cancers.

Pharmacy Practice News, Booth 510

pharmacypracticenews.com

Pharmacy Practice News offers fair-balanced, timely coverage of clinical developments and pharmacy operations. Our focus: to help readers provide high-quality patient care, and to demonstrate the value of that care to colleagues and hospital administrators. Coupled with pharmacist-written columns on reimbursement, technology and leadership, PPN is the must-read pharmacy publication.

Pharmacy Times, Booth 219 **Gold Sponsor**

Recordati Rare Diseases, Booth 309

recordatirarediseases.com/us

Our mission is to reduce the impact of extremely rare and devastating diseases by providing urgently needed therapies. We work side-by-side with rare disease communities to increase awareness, improve diagnosis and expand availability of treatments for people with rare diseases.

Regeneron Pharmaceuticals, Booth 308 **IRC**

Gold Sponsor

regeneron.com

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly translate science into medicine has led to numerous FDA-approved treatments and product candidates in development. Visit www.Regeneron.com to learn more.

Rocky Mountain Poison & Drug Safety, Booth 610

rmpds.org

Providing specialized FDA and global regulatory compliant medical information programs. Since our inception in 1978, we have developed industry best practices and gained complex case management experience, specializing in rare disease, oncology and other complex disease states, enabling your firm to stay in compliance with increasingly complex regulatory requirements.

Sanofi, Booth 307 **IRC** **Gold Sponsor**

sanofi.com/en

Sanofi is an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our teams across the world strive to transform the practice of medicine for patients. Our approach is shaped by our experience developing specialized treatments and forging relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.

Sanofi, Booth 422 **IRC** **Gold Sponsor**

sanofi.us

Sanofi's global specialty care business unit focuses on rare diseases, rare blood disorders, neurology, immunology, and oncology leveraging science and innovation to help improve people's lives. www.sanofi.us

Servier Pharmaceuticals, Booth 509 **IRC**

servier.us

Servier is a global leader in oncology focused on delivering meaningful therapeutic progress for the patients it serves. Governed by a non-profit foundation, Servier approaches innovation with a long-term vision, free of influence from investors and outside pressure to chase short-term monetary targets.

Shorla Oncology, Booth 620

shorlaoncology.com

Established in 2018 by Sharon Cunningham and Orlaith Ryan, Shorla Oncology is a privately held, U.S. and Ireland-based specialty pharmaceutical company with an advanced pipeline of innovative oncology drugs for orphan and pediatric cancers. The company concentrates on indications where existing treatments are limited, in shortage or the drug applications are inadequate for the target population. Shorla's growing portfolio brings accessible, affordable and life-saving treatments to patients, delivering a major contribution to patient care.

SOBI, Booth 420 **IRC**

sobi-northamerica.com

At Sobi North America, we are inspired by a single vision – to be recognized as a global leader in providing innovative medicines that transform the lives of people with rare and debilitating diseases. Patients affected by rare diseases often face bigger challenges. That's why we refuse to accept the status quo and are dedicated to making medicine more accessible. We are creating more possibilities for those otherwise overlooked.

Stemline Therapeutics, Inc., Booth 406 **IRC**

stemline.com

Stemline Therapeutics, a part of the Menarini Group, is focused on the development and commercialization of novel oncology therapeutics. The goal of our dedicated team of scientists, specialists, researchers, and developers is to build a leading biopharmaceutical company focused on improving the lives of cancer patients by developing novel therapeutics.

Syndax Pharmaceuticals, Inc., Booth 221

Taiho Pharmaceutical, Booth 223 **IRC**

taihooncology.com/us

EXPLORING INNOVATIONS THAT ENRICH LIVES WORLDWIDE We are leaders in cutting-edge science and technology, from chemistry to pharmacokinetics. This expertise and our unique vision allow us to consistently pursue and develop life-changing innovations.

Takeda, Booth 411

takeda.com

Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. www.takeda.com

The Journal of Hematology Oncology Pharmacy (JHOP), Booth 515

jhoponline.com

The Journal of Hematology Oncology Pharmacy is an independent, peer-reviewed journal founded in 2011 to provide hematology and oncology pharmacy practitioners and other healthcare professionals with high-quality peer-reviewed information relevant to hematologic and oncologic conditions to help them optimize drug therapy for patients.

CE SYMPOSIA

All sessions provide 1.0 CE

Wednesday, April 3

7:00 – 8:00 AM, Room 120-121

Navigating Chronic Lymphocytic Leukemia Therapy and Cardiovascular Comorbidities: Clinical Recommendations and Safety Measures

This activity is supported by educational grants from BeiGene USA, Inc. and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

This program will compare safety and efficacy data for Bruton tyrosine kinase inhibitors and other small-molecule inhibitors in the treatment of chronic lymphocytic leukemia to best guide selection of preferred regimens and anticipate and mitigate cardiovascular adverse effects.

7:00 – 8:00 AM, Room 122-123

Balancing Innovation and Implementation: A Comprehensive Approach to CAR T, Bispecific Antibodies, and Operational Efficiency in Multiple Myeloma

Victoria Nachar, PharmD, BCOP

Joseph A. Kalis, PharmD, BCOP

Rebecca Gonzalez, PharmD, BCOP

This activity is supported by an educational grant from Bristol Myers Squibb.

This activity will provide pharmacists with the knowledge necessary to positively impact patient outcomes through identification of treatment challenges and implementation of strategies for improved integration of CAR T-cell therapy and bispecific antibodies in the treatment of multiple myeloma.

7:00 – 8:00 AM, Room 124-125

Prescriptions for Successful Myeloma Care: Pharmacy Strategies for Delivering Effective Therapy With Antibody Platforms

R. Donald Harvey, III, PharmD, BCOP, FCCP, FHOPA

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA

James A. Davis, PharmD, BCOP

This activity is supported by independent medical education grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Regeneron Pharmaceuticals, Inc., and Sanofi.

Innovative antibody platforms have transformed myeloma care, offering patients a broader spectrum of therapeutic choices. For hematology-oncology pharmacists, these platforms pose tremendous opportunities and challenges. Learn the latest on CD38, BCMA, and non-BCMA antibody strategies and hear how pharmacists can lead the modernization of patient-, staff-, and institution-directed protocols.

Thursday, April 4

12:00 – 1:00 PM, Room 120-121

Elevating Safety and Adherence in Chronic Myeloid Leukemia Through Oncology Pharmacist Expertise

Peter Campbell, PharmD, MBA, BCOP

Benyam Muluneh, PharmD, BCOP, CPP

Jordan Snyder, PharmD, BCOP

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

This program will focus on BCR::ABL1-targeting tyrosine kinase inhibitors (TKIs) for the treatment of chronic myeloid leukemia. Patient cases will examine strategies for managing TKI therapies, optimizing adherence, and managing adverse effects.

12:00 – 1:00 PM, Room 122-123

Advancements in Early-Stage Breast Cancer: The Role of Oncology Pharmacists in Treatment Optimization

Danielle Roman, PharmD, BCOP

Allison R. Butts, PharmD, BCOP

Julia Ziegengeist, PharmD, BCOP

This activity is supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.

This session will review the oncology pharmacist's role in determining optimal treatment sequencing of targeted systemic therapies for patients with early-stage breast cancer.

12:00 – 1:00 PM, Room 124-125

What's New in NSCLC Therapies? Key Takeaways for Your Pharmacy Practice

Val Adams, PharmD, FCCP, BCOP

Whitney Lewis, PharmD, BCOP

CE Event supported by independent educational grants from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC, Regeneron, and Sanofi.

The treatment armamentarium for patients with NSCLC has expanded rapidly in recent times, making care of these patients more complex. Join us in Tampa to get the latest information on and best practices for the use of selected targeted therapies, immunotherapy, and antibody-drug conjugates for patients with NSCLC.

Friday, April 5

7:00 – 8:00 AM, Room 120-121

Optimizing JAK Inhibitor Therapy for Myelofibrosis: Insights for Oncology Pharmacists

Shawn Griffin, PharmD, BCOP

Amber Clemmons, PharmD, BCOP, FHOPA

James A. Davis PharmD, BCOP

This activity is sponsored by MJH Life Sciences™, the parent company of Pharmacy Times® and PTCE.

This activity will examine treatment sequencing of JAK inhibitors in myelofibrosis and equip pharmacists to optimize therapy regimens, minimize treatment-related toxicities, and provide evidence-based supportive care interventions.

7:00 – 8:00 AM, Room 122-123

Optimizing Bispecific Antibody Utilization in Non-Hodgkin Lymphoma: Addressing Challenges in Community-Based Care

Sara Moran Smith, PharmD, BCOP

Sarah (Stump) Profitt, PharmD, BCOP

Julio Chavez, MD

This activity is supported by an independent medical educational grant from Genmab.

This program features case discussions that will explore clinical and operational challenges in the use of BsAb therapies for patients with non-Hodgkin lymphomas.

7:00 – 8:00 AM, Room 124-125

Maximizing Efficacy and Minimizing Toxicity of ADCs Targeting HER2, HER3 and TROP2: Strategies for Oncology Pharmacists

Allison Butts, PharmD, BCOP

Sandra Cuellar, PharmD, BCOP, FHOPA, FASHP

This activity is sponsored by ProCE, LLC, in partnership with Clinical Care Options, LLC.

Join us for this 1-hour, CPE-certified symposium at HOPA AC24, where pharmacist experts will discuss current and emerging regimens leveraging ADCs directed against HER2, HER3, and TROP-2. Get up to date on how oncology pharmacists can optimize care for patients receiving ADCs, from patient education to toxicity identification and management.

Saturday, April 6

7:00 – 8:00 AM, Room 120-121

New Frontiers in the Treatment of Lower-Risk Myelodysplastic Syndromes (LR-MDS): Bridging Clinical Innovation and Practice

Anthony Perissinotti, PharmD, BCOP

Firas El Chaer, MD

Rachel Feaster, PharmD, BCOP, BCPS

This activity is supported by educational grants from Geron Corporation and Bristol Myers Squibb.

This educational activity and included patient case discussions will center around insights into newly emerging therapies and treatment protocols in lower-risk myelodysplastic syndromes to improve symptoms, enhance quality of life, and prolong survival for patients.

7:00 – 8:00 AM, Room 122-123

Enhancing Bruton Tyrosine Kinase Inhibitor Outcomes in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: A Pharmacist's Roadmap to Success

Karen M. Fancher, PharmD, BCOP

Melanie A. Rudisill, PharmD, BCOP

Alison Duffy, PharmD, BCOP

This activity is supported by an educational grant from Lilly.

This program will explore treatment expectations with covalent Bruton tyrosine kinase (BTK) inhibitor therapy for patients with B-cell malignancies and examine how the development of novel noncovalent BTK inhibitors may overcome existing treatment challenges.

ADVANCING INNOVATION ACROSS OUR BROAD PORTFOLIO

OPDIVO
(nivolumab)
INJECTION FOR INTRAVENOUS USE 10 mg/mL

OPDIVO
(nivolumab)
INJECTION FOR INTRAVENOUS USE 10 mg/mL

+ **YERVOY**
(ipilimumab)
Injection for intravenous use 5 mg/mL

OPDIVO
(nivolumab)
INJECTION FOR INTRAVENOUS USE 10 mg/mL

+ **CABOMETYX**
(cabozantinib) tablets
60 mg | 40 mg | 20 mg

Opdualag
(nivolumab and relatlimab-rmbw)
Injection for intravenous use | 480 mg/160 mg

AUGTYRO
(repotrectinib) 40 mg capsules

SCAN
or
VISIT

[OPDIVOHCP.com](https://www.opdivohcp.com)



[AUGTYROHCP.com](https://www.augtyrohcp.com)



OPDIVO, YERVOY, CABOMETYX, Opdualag, and AUGTYRO are available by prescription only.

OPDIVO® and YERVOY® are registered trademarks and Opdualag™ is a trademark of Bristol-Myers Squibb Company. CABOMETYX® and logo are registered trademarks of Exelixis, Inc.

AUGTYRO™ and the related logo are trademarks of Turning Point Therapeutics, Inc., a Bristol Myers Squibb company.

© 2024 Bristol-Myers Squibb Company.

466-US-2400001 01/24

Wednesday, April 3

12:00 – 1:00 PM, Room 120-121

Outcomes and Economic Impact of Treatment with CABLIVI®(caplacizumab-yhdp)

Hillary Maitland, MD, MS

Adam Gurry, MD, MS

This activity is sponsored by Sanofi.

This product theater will highlight the clinical and economic impact CABLIVI has had since its launch in 2019.

12:00 – 1:00 PM, Room 122-123

How Is the Treatment of Patients With KRAS G12C-Mutated Advanced NSCLC Evolving?

Sandra Cuellar, PharmD, BCOP, FHOPA, FASHP

Sponsored by Mirati – A Bristol Myers Squibb company.

12:00 – 1:00 PM, Room 124-125

Brukinsa (zanubrutinib) for the treatment of adult patient with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Bhavesh Shah, RPh, BCOP

This activity is sponsored by BeiGene.

This presentation developed for pharmacists, will educate on Brukinsa (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) through the review of clinical trial information and case studies. It will also touch on dosing and modifications, pharmacokinetics, pricing and distribution and BeiGene patient assistance program.

5:30 – 6:30 PM, Room 120-121

Planning for Treatment in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Case-Based Symposium on Care Team Preparation and Patient Management

Rebecca Nelson, PharmD, BCOP

Dylan Barth, PharmD

This activity is sponsored by Stemline.

This non-CE symposium will review efficacy and safety data in patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). A clinical simulation will be used to understand key aspects of care team and site preparation, patient monitoring and clinical management of potential adverse events.

5:30 – 6:30 PM, Room 122-123

Managing Patients with locally advanced or metastatic KRAS G12C-mutated NSCLC

Hatim Husain, MD

This activity is sponsored by Amgen.

Join us for a dinner presentation given by Dr. Hatim Husain of Moores of UC San Diego Health on “Managing Patients with KRAS G12C-mutated NSCLC,” highlighting LUMAKRAS® (sotorasib), a first-in-class, once-daily oral oncolytic. We'll discuss clinical trial results with a spotlight on best practices in patient biomarker identification, the drug's dosing guidelines, and adverse event management.

Thursday, April 4

7:00 – 8:00 AM, Room 120-121

Key Considerations for Operationalizing Bispecifics in Relapsed or Refractory Multiple Myeloma

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC

This activity is sponsored by Johnson & Johnson Innovative Medicine.

Explore operational considerations with RRMM bispecific therapies across 3 states of readiness: Facility readiness, Provider & care team readiness, and Patient & care partner readiness.

7:00 – 8:00 AM, Room 122-123

Managing Myelofibrosis: A Pharmacist's Perspective

Kyle Farina, PharmD, BCPS, BCOP

This activity is sponsored by GSK Medical Affairs.

Myelofibrosis is a rare myeloproliferative neoplasm characterized by constitutional symptoms, splenomegaly, bone marrow fibrosis, and cytopenias. This presentation will explore an in-depth disease state review, strategies for symptom management, and the role of pharmacists in monitoring and providing support for patients with myelofibrosis.

7:00 – 8:00 AM, Room 124-125

Essentials for Pharmacists: A Treatment Option for Relapsed or Refractory Multiple Myeloma From Pfizer

This activity is sponsored by Pfizer.

The presentation provides education on a therapeutic advancement for patients with relapsed or refractory multiple myeloma, including clinical trial data with pharmacist-specific considerations for therapy management, dosing, drug interactions, pharmacokinetics, and patient counseling.

NON-CE SYMPOSIA

Thursday, April 4

5:30 – 6:30 PM, Room 120-121

EMERALD study update: Exploring the safety and efficacy data in patients with ER+/HER2, ESR1-mutated mBC, including data from subgroup analyses

Scott Ostriker, PharmD, MBA, BCOP

This activity is sponsored by Stemline.

This non-CE symposium will review key safety and efficacy data from the phase 3 EMERALD trial in patients with ER+, HER2- mBC harboring ESR1 mutations. Safety and efficacy data for primary endpoint and in clinical subgroups, including patients with visceral metastases, co- mutations, HER2-low or HER2-zero expression, will be discussed.

5:30 – 6:30 PM, Room 122-123

Review of Evidence-Based Data for an Antibody-Drug Conjugate in Combination With a PD-1 Inhibitor for 1L la/mUC

This activity is sponsored by Pfizer.

Friday, April 5

12:00 – 1:00 PM, Room 120-121

Understanding the role of pharmacists in the management of Low-risk Myelodysplastic Syndromes (MDS)

David Sallman, MD

Katie Tobon, Pharm D, BCOP

This activity is sponsored by Bristol Myers Squibb.

A discussion between hemato-oncologist and pharmacist, sharing their perspectives on best practices to navigate barriers on diagnosis, new Myelodysplastic syndromes (MDS) classifications, prognostic risk scoring tool (IPSS-R and IPSS-M), and management of patients with MDS.

12:00 – 1:00 PM, Room 122-123

Practical Management of AML with a BCL-2 Inhibitor

This activity is sponsored by AbbVie.

This presentation will review the AML disease state and treatment landscape, and conduct a case-based discussion of the practical management of patients with AML receiving BCL-2 inhibitors.

12:00 – 1:00 PM, Room 124-125

Explore the current data that could help you recognize/ assess candidates for a CDK4 & 6 inhibitor.

Rodney J. Hunter, PharmD, BCOP

This activity is sponsored by Eli Lilly and Company.

Join this peer-led discussion to help determine when use of this CDK4 & 6 inhibitor may be appropriate and key recommendations to help manage potential side effects.

Saturday, April 6

11:45 AM – 12:45 PM, Room 120-121

Long-Term Clinical Trial Results for a BTKi in the Treatment of CLL/SLL

Mark Wagner, PharmD

This activity is sponsored by AstraZeneca.

CALQUENCE—A BTKi for the Treatment of CLL/SLL: This presentation has the most recent 6-year clinical trial data and includes two MAIC (Match Adjusted Indirect Comparison). You can expect a CALQUENCE overview, key clinical trial data in CLL, dosing/dosage modifications, key takeaways, two patient case studies, and information about support programs.

11:45 AM – 12:45 PM, Room 122-123

Harnessing the Power of Human Immunity

Greg Eskinazi, RPh, BCOP, CCRP

This activity is sponsored by Regeneron.

Program Overview:

- Clinical evidence from two large phase 3 clinical trials in certain patients with advanced NSCLC
- Efficacy and safety findings from clinical trials in advanced CSCC and advanced BCC
- Clinical trial patient cases



Booth Number: 314

AVEO Oncology (“AVEO”) is an oncology-focused biopharmaceutical company committed to providing innovative solutions to improve cancer patients lives. On January 20, 2023, AVEO was acquired by LG Chem, Ltd. (“LG Chem”), establishing a U.S. commercial presence for LG Chem and expanding LG Chem’s global oncology portfolio. AVEO continues to commercialize FOTIVDA® (tivozanib) in the U.S. To learn more about FOTIVDA efficacy, safety, and relevant resources, visit FOTIVDAHCP.com.



Booth Number: 718

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines.



A Member of the Roche Group

Booth Number: 323

Genentech pioneered the biotech industry and continues to pursue revolutionary science and develop life-changing medicines to treat some of the world’s most complex health problems. Learn more at gene.com.



moved by you

Booth Number: 509

Servier Pharmaceuticals is a commercial-stage pharmaceuticals company with a passion for innovation and improving the lives of patients, their families and caregivers. With our commercial and scientific expertise, global reach, commitment to clinical excellence, Servier Pharmaceuticals is dedicated to bringing the promise of tomorrow to the patients that we serve.

THANK YOU TO OUR ANNUAL CONFERENCE PLANNING COMMITTEE AND SUBCOMMITTEES!

Annual Conference Committee:

Chair: Maribel Pereiras, PharmD, BCOP, BCPS

Vice Chair: Katherine Morgan, PharmD, BCOP, CPP

Past Chair: Brooke Adams, PharmD, BCOP

Jessica Auten, PharmD, BCOP

Alexa Basilio, PharmD, BCOP

Laura Bobolts, PharmD, BCOP

Robert Mancini, PharmD, BCOP, FHOA

Bernard Marini, PharmD, BCOP

Jane Rogers, PharmD, BCOP

Cassandra Rush, PharmD, BCOP

Thomas Schultz, PharmD, BCOP

Peter Stuessy, PharmD, BCOP

Kyle Zacholski, PharmD, BCOP

Jennifer Zadlo, PharmD, BCOP

Mark, Zangardi PharmD, MS, BCOP

Annual Conference Breakout Session Subcommittee:

Chair: Alexis Chapman, PharmD, BCOP

Vice Chair: Alyssa Heiden, PharmD, BCOP

Jordanne Adolphsen, PharmD, BCOP

Lauren Bodhaine Haywood, PharmD, BCOP, BCPS

Lindsey Douglass, PharmD, BCPS, BCOP

Christina Gullion, PharmD, BCOP

Megan Hinkley, PharmD, BCOP

Erica Hochard, PharmD, BCOP

Lindsey Jung, PharmD, BCPS

Kara Kubli, PharmD, BCOP

Madeleine Ochs, PharmD, BCOP

Danielle Schlafer, PharmD, BCOP

Rachael Straining, PharmD, BCOP

Sarah Tucker, PharmD, BCOP

BCOP Conference Planning Subcommittee:

Chair: Jennifer Kwon, PharmD, BCOP

Vice Chair: Michelle Worst, PharmD, BCOP, MBA

Matthew Arango, PharmD, BCOP

Sal Bottiglieri, PharmD, BCOP

Jill Comeau, PharmD, BCOP

Emily Dworkin, PharmD, BCOP

Angela German, PharmD, BCOP

Whitney Lewis, PharmD, BCOP

Jonathan Savoy, PharmD, BCOP

Allison Schepers, PharmD, BCOP

Sarah Timaeus, PharmD, BCOP

Kristin Wheatley, PharmD, BCOP

Annual Conference Abstract Review Subcommittee:

Chair: Sara Kim, PharmD, BCOP

Vice Chair: Adam DiPippo, PharmD

Laura Alwan, PharmD, BCOP

Young Bae, PharmD, BCOP, BCPS

Marisela Banez, PharmD, BCOP, BCPS

Courtney Cavalieri, PharmD, BCOP

Matthew Lei, PharmD, BCOP

Tristan Maiers, PharmD, BCOP

Colleen McCabe, PharmD, BCOP

Kristen McCullough, PharmD, BCPS, BCOP

Jian Ni, PharmD, MPH, BCOP

Teresa Rushing, PharmD, BCPS, BCOP

Paula Sayegh, PharmD, BCPS, BCOP

Michael Williams, PharmD, BCOP

For the treatment of newly diagnosed, IC-ineligible acute myeloid leukemia (AML)

COULD WAITING FOR TEST RESULTS GIVE YOUR PATIENTS MORE TIME?

Does molecular profiling help drive your treatment selection in newly diagnosed AML? **It should.** Mutated *IDH1* (*mIDH1*) is an oncogenic driver in up to 10% of AML cases.¹ More importantly, *mIDH1* is an actionable target for treatment. That's why both the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]) and the ASH-CAP Guidelines recommend performing molecular and cytogenetic analyses to identify *IDH1* mutations in patients with AML.^{2,3} Further, the NCCN Guidelines[®] recommend expediting these analyses.²

So the next time you have a patient with newly diagnosed, IC-ineligible AML, test for *IDH1* mutation status BEFORE choosing treatment—your first step to treatment selection could be your patient's first step to better outcomes.



Learn more at [AMLTreatmentOption.com](https://www.AMLTreatmentOption.com)

ASH, American Society of Hematology; CAP, College of American Pathologists; IC, induction chemotherapy; *IDH1*, isocitrate dehydrogenase-1; NCCN, National Comprehensive Cancer Network.

References: 1. Molenaar RJ, Maciejewski JP, Wilmink JW, van Noorden CJF. Wild-type and mutated *IDH1/2* enzymes and therapy responses. *Oncogene*. 2018;37(15):1949-1960. doi:10.1038/s41388-017-0077-z 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]) for Acute Myeloid Leukemia V.2.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed October 18, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 3. Arber DA, Borowitz MJ, Cessna M, et al. Initial diagnostic workup of acute leukemia: guideline from the College of American Pathologists and the American Society of Hematology. *Arch Pathol Lab Med*. 2017;141(10):1342-1393. doi:10.5858/arpa.2016-0504-CP



SARCLISA[®]

(isatuximab-irfc)

Injection for IV use | 500 mg/25 mL, 100 mg/5 mL

See the latest data for **SARCLISA + Kd**

Explore the full results of the
IKEMA phase 3 trial at
sarclisahcp.com



Kd=Kyprolis (carfilzomib) and dexamethasone

THANK YOU, IRC PARTNERS, FOR YOUR VALUED SUPPORT!

PREMIER



EXECUTIVE



ASSOCIATE



EMERGING





Save the Date
HOPA2025
PORTLAND,
OREGON
April 9-12, 2025



HOPA
Hematology/Oncology
Pharmacy Association



Mark your calendars for HOPA's Annual Conference 2025 in Portland, Oregon.
Expect five days of great topics, speakers and networking in a city filled with history and natural beauty.